CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or the "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumors, today issued a statement to address recent statements containing inaccurate and misleading claims regarding the Company's research programs, clinical progress, and operations.

CytoMed categorically rejects such claims which have no basis. Certain statements circulating publicly mis-characterize the Company's scientific focus, development status, and regulatory standing. Please refer to recent announcements by the Company on our progress.

CytoMed's research is focused on CAR γδ T cell therapies and iPSC-derived γδ NKT cell therapies, based on established immunological science. The Company's lead CAR γδ T cell program has received regulatory approval to proceed with a first-in-human (FIH) clinical trial, which is currently ongoing at National University Hospital (NUH), Singapore. This clinical activity is conducted in accordance with applicable regulatory and ethical requirements.